Table 2.
Characteristics of Patients with Mild or Severe COVID-19 Infection
| Characteristic | Severe COVID-19 (n = 7) | Mild COVID-19 (n = 32) | P |
|---|---|---|---|
| Mean age (in years) (SD) | 65.4 (17.4) | 41.3 (16.4) | 0.001 |
| Sex | 0.02 | ||
| Male | 0% | 47% | |
| Female | 100% | 53% | |
| Race | 0.078 | ||
| White | 71% | 94% | |
| Nonwhite / missing | 29% | 6% | |
| IBD-type | 0.38 | ||
| Crohn’s disease | 29% | 47% | |
| Ulcerative colitis | 71% | 53% | |
| Comorbidities | |||
| Obesity | 71% | 19% | 0.005 |
| Diabetes mellitus | 29% | 3% | 0.02 |
| Hypertension | 57% | 9% | 0.003 |
| Asthma | 29% | 6% | 0.078 |
| Medication category | 0.05 | ||
| 5-aminosalicylates | 71% | 22% | |
| Immunomodulator | 0% | 9% | |
| TNF-antagonists | 0% | 41% | |
| Vedolizumab | 29% | 16% | |
| Ustekinumab | 0% | 0% | |
| Tofacitinib | 0% | 0% | |
| Combination therapya | 0% | 13% | |
| Prednisone use | 0.83 | ||
| No | 75% | 80% | |
| Yes | 25% | 20% |
aCombination therapy refers to use of TNF-antagonists, vedolizumab, or ustekinumab in combination with an immunomodulator (azathioprine, mercaptopurine, methotrexate).